Clinical trial • Phase I • Oncology
Atezolizumab for Locally advanced or metastatic solid tumor|Ovarian cancer|Clear cell renal cell carcinoma
Phase I trial of Atezolizumab for Locally advanced or metastatic solid tumor|Ovarian cancer|Clear cell renal cell carcinoma. None/Not specified-controlled.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Locally advanced or metastatic solid tumor|Ovarian cancer|Clear cell renal cell carcinoma
- Trial Stage
- Phase I
- Drug Modality
- Monoclonal antibody|Other
Key dates
- Initial CTIS Submission Date
- 22-10-2024
- First CTIS Authorization Date
- 18-02-2025
Trial design
None/Not specified-controlled Phase I trial across 7 sites in Spain, Czechia.
- Comparator
- None/Not specified
- Target Sample Size
- 111
Eligibility
Recruits 111 Vulnerable population not selected; no vulnerable population consent or assent handling specified..
- Vulnerable Population
- Vulnerable population not selected; no vulnerable population consent or assent handling specified.
Recruitment
- Planned Sample Size
- 111
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 23
Spain
- Earliest CTIS Part Ii Submission Date
- 05-11-2024
- Latest Decision Or Authorization Date
- 25-03-2026
- Processing Time Days
- 505
- Number Of Sites
- 5
- Number Of Participants
- 15
Sites
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Servicio de oncologia
- Contact Person Name
- Bernard Doger de Speville Uribe
- Contact Person Email
- bernard.doger@startmadrid.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Servicio de oncologia
- Contact Person Name
- Ignacio Melero Bermejo
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Servicio de oncologia
- Contact Person Name
- Andres Cervantes Ruiperez
- Contact Person Email
- andres.cervantes@uv.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Servicio de oncologia
- Contact Person Name
- Ignacio Melero Bermejo
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Servicio de oncologia
- Contact Person Name
- Cristina Suarez Rodriguez
- Contact Person Email
- csuarez@vhio.net
Czechia
- Earliest CTIS Part Ii Submission Date
- 18-02-2025
- Latest Decision Or Authorization Date
- 30-03-2026
- Processing Time Days
- 405
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- University Hospital Olomouc
- Contact Person Name
- Bohuslav Melichar
- Contact Person Email
- Bohuslav.melichar@fnol.cz
- Site Name
- Masarykuv Onkologicky Ustav
- Contact Person Name
- Radka Lordick Obermannová
- Contact Person Email
- obermannova@mou.cz
Sponsor
Primary sponsor
- Full Name
- Genentech Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- RO7566802
- Modality
- Other
- Investigational Product Name
- Atezolizumab
- Active Substance
- Atezolizumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)